Oppenheimer downgraded CinCor Pharma from Outperform to Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/7/2022 | $22.00 | Overweight | Barclays |
| 11/29/2022 | Outperform → Perform | Oppenheimer | |
| 11/29/2022 | $60.00 → $22.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/28/2022 | $67.00 | Buy | Goldman |
| 8/22/2022 | $73.00 | Overweight | Piper Sandler |
| 2/1/2022 | Outperform | Evercore ISI | |
| 2/1/2022 | $30.00 | Outperform | Oppenheimer |
| 2/1/2022 | $27.00 | Overweight | Morgan Stanley |
-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent
- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of
Barclays initiated coverage of CinCor Pharma with a rating of Overweight and set a new price target of $22.00
Oppenheimer downgraded CinCor Pharma from Outperform to Perform
Morgan Stanley downgraded CinCor Pharma from Overweight to Equal-Weight and set a new price target of $22.00 from $60.00 previously
SC 13D/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC 13D/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC 13D/A - CinCor Pharma, Inc. (0001868734) (Subject)
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of
Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP) 12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a pre-specified subgroup that represents approximately 81-89% of the U.S. hypertension population (nominal p-value = 0.001) Safety profile and tolerability consistent with BrigHtn Phase 2 data; no patient discontinued due to treatment-related adverse events; low hyperkalemia incidence HALO in combination with BrigHtn informs the dose and study populations anticipated to be recruited into Phase 3 trials pending confirmation by FDA at planned end of Phase 2 meeting in January 2023; Phase 3 trials expec
Aldosterone and renin biomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol 20.3 mmHg reduction in systolic blood pressure, or 11 mmHg (p-value < 0.0001) placebo-adjusted decline at the 2 mg dose Well-tolerated profile and differentiated mechanism of action supports combination approaches Conference call and live webcast Tuesday November 8th, 2022 at 7 AM Eastern Time WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. ("CinCor") announced the presentation today of Phase 2 data from its BrigHtn trial as part of the late-breaking science session at the 2022 American Heart A
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
8-K - CinCor Pharma, Inc. (0001868734) (Filer)
25-NSE - CinCor Pharma, Inc. (0001868734) (Subject)
SC 14D9/A - CinCor Pharma, Inc. (0001868734) (Subject)